ClinicalTrials.gg
CompletedNCT03884491Updated Aug 1, 2019

A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

A Phase 1 interventional study of Vortioxetine IV and Vortioxetine SLA in Healthy, sponsored by H. Lundbeck A/S. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-08-01.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study investigates formulations of vortioxetine applied under the tongue

Read the detailed description

Apart from the first two doses, the study design is flexible in terms of doses and pharmaceutical formulations and will be decided upon based on an evaluation of the safety and tolerability as well as plasma exposure obtained during the study.

  • The study consists of 5 periods. Single-doses of vortioxetine will be administered in all periods.
  • All subjects will receive the same pharmaceutical formulations of the same dose strength in the same period and sequence.
  • In Period 1, each subject will receive an intravenous (IV) 10 mg dose of vortioxetine infused over 2 hours. The exposure obtained after IV administration will serve as the reference for the sublingually administered dosage forms.
  • In Period 2, each subject will receive 5 mg of formulation A (SLA) of vortioxetine in a sublingual (SL) formulation with a holding time of 90 seconds. The holding time is the time where swallowing of saliva should be avoided.
  • For the 3 remaining dosing periods, one or more of the following options in pharmaceutical formulation, dose, and dosing condition apply to this study:

    • Increases or decreases in dose (≤25mg) using same formulation
    • Change from formulation SLA to formulation SLB
    • Change in the holding time
    • Change to formulation SLC
    • Change in swallowing technique of the sublingual dosage forms
02

Conditions studied

  • Healthy
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-The subject has a ≥18.5 and ≤30.0 kg/m2 at the Screening Visit and at the Baseline Visit.

Exclusion criteria

Exclusion Criteria:

-The subject is identified or confirmed to be a CYP2D6 poor metabolizer (PM)

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Vortioxetine

    Drug: Vortioxetine IV · Drug: Vortioxetine SLA · Drug: Vortioxetine SLB · Drug: Vortioxetine SLC

Interventions

  • an intravenous (IV) 10 mg dose (1 mg/mL) of vortioxetine infused over 2 hours

  • DrugVortioxetine SLA

    5-25 mg of sublingual formulation A of vortioxetine

  • DrugVortioxetine SLB

    5-25 mg of sublingual formulation B of vortioxetine

  • DrugVortioxetine SLC

    formulation SLC: solution of vortioxetine, concentrate (12.5 mg/mL-62,5 mg/mL) 200 uL or 400 uL, SL, 5-25 mg

06

What researchers measure

Primary outcomes

  1. absolute bioavailability (F)

    absolute bioavailability of vortioxetine for the sublingual administrations

    Time frame: From predose to 72 hours post dose

  2. tmax

    time to maximum plasma concentration (tmax)

    Time frame: From predose to 72 hours post dose

07

Study locations

1 site
  • Quotient Sciences Ltd
    Nottingham, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Jun 2019, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2019
First posted
Mar 21, 2019
StartActual
Mar 18, 2019
Primary completionActual
Jun 25, 2019
CompletionActual
Jul 22, 2019
Last update
Aug 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03884491
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 21, 2019
Start date
Mar 18, 2019
Primary completion
Jun 25, 2019
Completion
Jul 22, 2019
Last update
Aug 1, 2019

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion